Published in J Immunother Cancer on March 15, 2016
Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells. Immunol Cell Biol (2017) 1.05
T cell receptor repertoire usage in cancer as a surrogate marker for immune responses. Semin Immunopathol (2017) 0.85
The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Front Immunol (2016) 0.80
Standardized and flexible eight colour flow cytometry panels harmonized between different laboratories to study human NK cell phenotype and function. Sci Rep (2017) 0.75
Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy. JCI Insight (2017) 0.75
Administration of a vasoactive intestinal peptide antagonist enhances the autologous anti-leukemia T cell response in murine models of acute leukemia. Oncoimmunology (2017) 0.75
Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma. Oncoimmunology (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Apoptosis in the pathogenesis and treatment of disease. Science (1995) 20.24
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI project. Nat Biotechnol (2008) 12.96
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med (2011) 12.58
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00
The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med (2013) 10.63
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature (2014) 10.49
PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10
Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature (1998) 9.77
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood (2002) 8.76
Innate or adaptive immunity? The example of natural killer cells. Science (2011) 8.68
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov (2011) 7.65
Human natural killer cells. Blood (2008) 7.37
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood (2005) 7.28
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature (2005) 7.18
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature (2002) 7.07
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol (2008) 6.90
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol (2003) 6.77
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73
Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol (2011) 5.63
Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 5.62
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med (2014) 5.60
Breakthrough of the year 2013. Cancer immunotherapy. Science (2013) 5.05
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med (2013) 4.86
Immunogenic and tolerogenic cell death. Nat Rev Immunol (2009) 4.34
Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med (2008) 4.33
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med (2005) 4.32
In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol (2010) 3.88
Standardizing immunophenotyping for the Human Immunology Project. Nat Rev Immunol (2012) 3.81
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A (2008) 3.80
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother (2009) 3.70
Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med (2003) 3.60
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res (2005) 3.57
Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity (2013) 3.50
Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol (2012) 3.43
Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol (2011) 3.41
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol (2009) 3.20
Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst (2013) 3.07
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer (2010) 3.03
Cancer immunology--analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol (2011) 2.90
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity (2013) 2.86
Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene (2009) 2.74
Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J (2009) 2.72
Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity (2013) 2.69
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. BMC Immunol (2005) 2.31
An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res (2013) 2.30
Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res (2014) 2.25
Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med (2005) 2.12
A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med (1991) 2.07
Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med (2011) 2.04
In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood (2011) 2.02
A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy (2010) 1.99
Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia. J Clin Oncol (2005) 1.91
Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci U S A (2006) 1.88
Harmonization of immune biomarker assays for clinical studies. Sci Transl Med (2011) 1.84
Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol (2010) 1.84
Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res (2003) 1.83
Immunosequencing: applications of immune repertoire deep sequencing. Curr Opin Immunol (2013) 1.76
A model for harmonizing flow cytometry in clinical trials. Nat Immunol (2010) 1.70
BCG and cancer. N Engl J Med (1974) 1.66
Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol (2013) 1.65
Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res (2013) 1.63
Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med (2012) 1.63
The immunologic constant of rejection. Trends Immunol (2008) 1.62
Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. J Clin Invest (2012) 1.55
Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. Methods (2014) 1.55
Combination checkpoint blockade--taking melanoma immunotherapy to the next level. N Engl J Med (2013) 1.45
FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Ann Oncol (2010) 1.42
Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother (2010) 1.42
Diversity and recognition efficiency of T cell responses to cancer. PLoS Med (2004) 1.36
Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology (2013) 1.36
Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology (2014) 1.35
High-throughput sequencing of T-cell receptors reveals a homogeneous repertoire of tumour-infiltrating lymphocytes in ovarian cancer. J Pathol (2013) 1.31
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med (2013) 1.31
TNM staging in colorectal cancer: T is for T cell and M is for memory. J Clin Oncol (2011) 1.30
Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest (2014) 1.29
Cancer: Antitumour immunity gets a boost. Nature (2014) 1.28
Immune response against dying tumor cells. Adv Immunol (2004) 1.26
Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition. Clin Cancer Res (2013) 1.26
Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res (2014) 1.24
Gene-expression profiling in vaccine therapy and immunotherapy for cancer. Expert Rev Vaccines (2010) 1.15
Immune modulation for cancer therapy. Br J Cancer (2014) 1.15
Immunohistochemical detection of cytoplasmic LC3 puncta in human cancer specimens. Autophagy (2012) 1.12
Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ (2013) 1.12
Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas. J Pathol (2013) 1.09
CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood (2014) 1.09
Cytokine assays: an assessment of the preparation and treatment of blood and tissue samples. Methods (2013) 1.09